[go: up one dir, main page]

WO2008021048A3 - Adp-ribosyltransferase based methods and compositions - Google Patents

Adp-ribosyltransferase based methods and compositions Download PDF

Info

Publication number
WO2008021048A3
WO2008021048A3 PCT/US2007/017461 US2007017461W WO2008021048A3 WO 2008021048 A3 WO2008021048 A3 WO 2008021048A3 US 2007017461 W US2007017461 W US 2007017461W WO 2008021048 A3 WO2008021048 A3 WO 2008021048A3
Authority
WO
WIPO (PCT)
Prior art keywords
adp
ribosyltransferase
compositions
based methods
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/017461
Other languages
French (fr)
Other versions
WO2008021048A2 (en
Inventor
David A Sinclair
Ron Firestein
Basil Hubbard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008021048A2 publication Critical patent/WO2008021048A2/en
Publication of WO2008021048A3 publication Critical patent/WO2008021048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are methods for identifying agents that modulate the activity of sirtuin ADP ribosyltransferases, e.g., Sirt4 and Sirt6. Also provided are methods for treating a hyperproliferating disease, comprising, e.g., administering to a subject in need thereof an agent that reduces the activity or protein level of an ADP ribosyltransferase, e.g., Sirt6.
PCT/US2007/017461 2006-08-07 2007-08-06 Adp-ribosyltransferase based methods and compositions Ceased WO2008021048A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83603506P 2006-08-07 2006-08-07
US83600806P 2006-08-07 2006-08-07
US60/836,008 2006-08-07
US60/836,035 2006-08-07

Publications (2)

Publication Number Publication Date
WO2008021048A2 WO2008021048A2 (en) 2008-02-21
WO2008021048A3 true WO2008021048A3 (en) 2008-09-04

Family

ID=39082544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017461 Ceased WO2008021048A2 (en) 2006-08-07 2007-08-06 Adp-ribosyltransferase based methods and compositions

Country Status (1)

Country Link
WO (1) WO2008021048A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137345A1 (en) * 2007-05-14 2010-06-03 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
KR102043303B1 (en) * 2013-03-08 2019-11-12 한국화학연구원 Method for quantitative analysis of SIRT7-deacetylation activity and method for screening SIRT-7 inhibitors using the same
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
CN114958960B (en) * 2022-01-07 2025-07-25 河南省人民医院 Drug screening method of target histone deacetylase SIRT6 regulator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRYE ET AL.: "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity", BIOCHEM. BIPHYS. RES. COMMUN., vol. 260, no. 1, 24 June 1999 (1999-06-24), pages 273 - 279, XP002963940 *
HONES ET AL.: "Studies of enzyme-ligand complexes using dynamic fluorescence anisotropy. II. The coenzyme-binding site of malate dehydrogenase", BIOL. CHEM. HOPPE SEYLER, vol. 367, no. 2, February 1986 (1986-02-01), pages 103 - 108 *

Also Published As

Publication number Publication date
WO2008021048A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
EP2068875A4 (en) COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY
MX2008012400A (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity.
NO20060871L (en) Azepine derivatives as pharmaceutical agents
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
BR112013008140A2 (en) "imidazotriazinone compounds".
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PT2275097T (en) COMPOSITIONS INCLUDING CANABINOIDS FOR THE TREATMENT OF NAUSES, VOMITING, EMMESIS, SICKNESS OR IDENTICAL CONDITIONS
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
WO2012027065A3 (en) Combination therapy for treatment of disease
TW200612926A (en) Compounds and compositions as ppar modulators
DE602006013191D1 (en) SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXYLIC ACIDS ARE EFFECTIVE PARP INHIBITORS
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
EP2279244A4 (en) METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
MX2007009356A (en) Compounds and compositions as ppar modulators.
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
FI20011403A7 (en) Method and compositions for treating stomach diseases
TW200602330A (en) Compounds and compositions as PPAR modulators
BRPI0718469A2 (en) USE OF AN INTERLEUCIN 1 ANTAGONIST (IL-1), METHOD FOR TREATING, INHIBITING OR IMPROVING PSEUDOGOTA, USE OF ONE OR MORE THERAPEUTIC AGENTS, AND, PRODUCT.
BRPI0512500A (en) treatment or conditions involving demyelination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811104

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07811104

Country of ref document: EP

Kind code of ref document: A2